"Imatinib Mesylate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
Descriptor ID |
D000068877
|
MeSH Number(s) |
D02.065.277.456 D02.241.223.100.100.435 D02.455.426.559.389.127.085.465 D03.383.606.405 D03.383.742.349
|
Concept/Terms |
Imatinib Mesylate- Imatinib Mesylate
- Mesylate, Imatinib
- Imatinib Methanesulfonate
- Methanesulfonate, Imatinib
Imatinib- Imatinib
- Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
|
Below are MeSH descriptors whose meaning is more general than "Imatinib Mesylate".
Below are MeSH descriptors whose meaning is more specific than "Imatinib Mesylate".
This graph shows the total number of publications written about "Imatinib Mesylate" by people in this website by year, and whether "Imatinib Mesylate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 6 | 6 |
2002 | 0 | 20 | 20 |
2003 | 0 | 48 | 48 |
2004 | 0 | 45 | 45 |
2005 | 0 | 31 | 31 |
2006 | 0 | 48 | 48 |
2007 | 0 | 71 | 71 |
2008 | 0 | 59 | 59 |
2009 | 0 | 59 | 59 |
2010 | 0 | 61 | 61 |
2011 | 0 | 40 | 40 |
2012 | 0 | 42 | 42 |
2013 | 0 | 30 | 30 |
2014 | 1 | 21 | 22 |
2015 | 3 | 12 | 15 |
2016 | 11 | 7 | 18 |
2017 | 4 | 4 | 8 |
2018 | 6 | 8 | 14 |
2019 | 6 | 5 | 11 |
2020 | 3 | 5 | 8 |
2021 | 2 | 5 | 7 |
2022 | 0 | 6 | 6 |
2023 | 0 | 6 | 6 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imatinib Mesylate" by people in Profiles.
-
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1).
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30(2):498-506.
-
Project Confirm: Accelerated Drug Approvals for CML-Response. Clin Cancer Res. 2024 01 05; 30(1):237-238.
-
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica. 2023 Dec 01; 108(12):3454-3459.
-
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Mar; 24(3):149-157.
-
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023 12 01; 129(23):3805-3814.
-
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer. 2023 10; 192:113245.
-
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520.
-
Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58.
-
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022 Nov; 9(11):e854-e861.